



August 31, 2019

New frontiers: SGLT2 inhibitors in cardiorenal disease

Reykjavik - Village 2

Sat 31 Aug, 11:00 - 12:30, Anti-Diabetic Pharmacotherapy, Advances in Science

Chairpersons: Stephen **WIVIOTT**, Mikhail KOSIBOROD

11:00: State of the Art - SGLT2 inhibitors in cardiovascular disease, Marc **SABATINE**

11:18: Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58, Thomas **ZELNIKER**

Experts on the spot: expanding knowledge on glucagon-like peptide-1 receptor agonists in cardiometabolic care

Duras - The Hub

Sat 31 Aug, 12:45 - 13:15, Cardiovascular Disease in Special Populations, Satellite Symposium - Experts on the Spot

Chairperson: Erin **BOHULA**

12:45: Glucagon-like peptide-1 receptor agonist treatment landscape: highlighting the benefits of cardiovascular risk reduction, Erin **BOHULA**

13:00: The future of cardiometabolic care: the impact of glucagon-like peptide-1 receptor agonists, Benjamin Morgan **SCIRICA**

The right glucose-lowering drugs for the right patient

Reykjavik - Village 2

Sat 31 Aug, 13:45 - 14:55, Diabetes and the Heart: Pharmacotherapy, Advances in Science, Abstract-based Programme

14:37 Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus, David **BERG**

Perspectives on anticoagulation across cardiovascular disease

Agora 1 - Poster Area

Sat 31 Aug, 13:45 - 15:00, Anticoagulants, Rapid Fire Abstracts, Abstract-based Programme

14:50 Edoxaban versus warfarin in atrial fibrillation patients with low, mid and high body weight: analysis of outcomes in the **ENGAGE-AF TIMI 48** trial, Giuseppe BORIANI

PCSK9i, changing practice in cardiology: the emerging story

Tbilisi - Village 6

Sat 31 Aug, 15:30 - 16:30, Risk Factors and Prevention, Satellite Symposium

15:50: Extending the evidence: what did the FOURIER trial learn us on managing high risk patients?, Marc **SABATINE**

September 01, 2019

Treatment of conundrum in acute heart failure

Sarajevo - Village 5

Sun 01 Sep, 08:30 - 10:00, Acute Heart Failure, Advances in Science

09:42: Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial., David **MORROW**

Eugene Braunwald and ESC Women in cardiology

ESC TV Stage - ESC Plaza

Sun 01 Sep, 12:45 - 13:15, European Society of Cardiology - Other, Interview

12:45: Eugene Braunwald and ESC Women in cardiology., Eugene **BRAUNWALD**



September 02, 2019

Poster Session 4: Advanced heart failure

Posters - Poster Area

Mon 02 Sep, 08:30 - 12:30, Poster Session, Abstract-based Programme

08:30: Heart Failure hospitalization and mortality in non-valvular Atrial Fibrillation: The **ENGAGE-AF TIMI 48** Trial, Riccardo Maria INCIARDI

Expert Advice - Best practice in acute coronary syndromes

Helsinki - Village 8

Mon 02 Sep, 11:00 - 12:30, Acute Coronary Syndromes – Treatment, Focus with the Experts

Chairpersons: Catherine KELLS, Eugene **BRAUNWALD**

The role of cardiac biomarkers to aid in diagnosis and risk stratification of cardiac diseases

Mon 02 Sep, 13:00 - 14:00, Acute Heart Failure, Satellite Symposium

Sofia - Village 8

13:15: ENGAGE-AF, the role of blood-based biomarkers for the risk-prediction of atrial fibrillation patients as part of the ABC risk scores, David **MORROW**

Anticoagulation in the aging atrial fibrillation population - Perspectives from clinical trials and routine daily practice

Astana - Village 2

Mon 02 Sep, 13:00 - 14:00, Atrial Fibrillation, Satellite Symposium

13:20: Risks and benefits of anticoagulation in the elderly - Insights from randomized trials, Robert P **GIUGLIANO**

The north face in acute coronary syndromes: let's climb it!

Berlin - Village 4

Mon 02 Sep, 13:00 - 14:00, Acute Coronary Syndromes, Satellite Symposium

Chairperson: Marc **SABATINE**

13:00: LDL-C treatment after acute coronary syndromes: a fresh perspective, Marc **SABATINE**

13:30: The future is now, Marc **SABATINE**, Konstantinos KOSKINAS

Poster Session 5: Acute coronary syndrome treatment

Posters - Poster Area

Mon 02 Sep, 14:00 – 18:00, Lipids, Special Session

14:00: Comparing biomarker profiles in patients with stable atherosclerosis treated with anacetrapib versus placebo: a nested proteomic study from HPS3/TIMI 55-REVEAL, David **BERG**

Professor Braunwald's perspective on lipid lowering

Colette - The Hub

Mon 02 Sep, 14:30 - 15:15, Poster Session, Abstract-based Programme

14:00: What is the right age to start lipid lowering therapy., Eugene **BRAUNWALD**

Progress in secondary prevention - New treatments

Science Box 1 - Poster Area

Mon 02 Sep, 14:30 - 15:40, Risk Factors and Prevention, Abstract Session

Chairpersons: Furio COLIVICCHI, Marc **SABATINE**

The north face in acute coronary syndromes: let's climb it!

Hugo - The Hub

Mon 02 Sep, 16:00 - 16:30, Acute Coronary Syndromes, Satellite Symposium - Experts on the Spot

Chairpersons: Marc **SABATINE**

Acute heart failure: new treatment updates

Science Box 2 - Poster Area

Mon 02 Sep, 16:40 - 17:50, Acute Heart Failure– Treatment, Abstract Session

17:22: Safety and efficacy of sacubitril/valsartan by dose level in patients hospitalized with acute heart failure: Observations from PIONEER-HF, David **MORROW**



September 03, 2019

Evolving concepts in lipidology

Prague - Village 2

Tue 03 Sep, 08:30 - 10:00, Lipids: Drug therapy, Symposium

08:30: LDL: how low should we go? Marc **SABATINE**

Improving cardiovascular risk in patients with obesity

Athens - Village 3

Tue 03 Sep, 13:00 - 14:00, Cardiovascular Disease in Special Populations, Satellite Symposium

Chairpersons: Lars RYDEN (Stockholm, Sweden)

13:20: What do we know from cardiovascular outcomes trials in obesity? Erin **BOHULA**

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Duras - The Hub

Tue 03 Sep, 16:00 - 16:30, Cardiovascular Disease in Special Populations, Satellite Symposium - Experts on the Spot

16:15: Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction, Benjamin Morgan **SCIRICA**